TRANSDERMAL DRUG DELIVERY SYSTEMS FOR CHRONIC DISEASE MANAGEMENT

Chronic diseases represent a significant global health challenge and often necessitate prolonged 
or lifelong pharmacotherapy to achieve optimal therapeutic outcomes and prevent disease 
progression. Conventional drug delivery routes, particularly oral and parenteral administration, 
are frequently associated with several drawbacks, including poor patient adherence, 
gastrointestinal side effects, inconsistent bioavailability, and extensive hepatic first-pass 
metabolism. These limitations are further intensified during long-term treatment, where repeated 
dosing and fluctuating plasma drug concentrations may negatively affect therapeutic efficacy. 
Consequently, there is an increasing need for alternative drug delivery strategies that can offer 
sustained, safe, and patient-friendly treatment options. Transdermal Drug Delivery Systems 
(TDDS) have gained considerable attention as an effective alternative for the management of 
chronic diseases by facilitating controlled drug transport across the skin directly into systemic 
circulation. The transdermal route provides multiple advantages, such as bypassing first-pass 
metabolism, maintaining consistent plasma drug levels, minimizing dosing frequency, and 
enhancing patient compliance. These benefits make TDDS particularly advantageous for chronic 
conditions including cardiovascular disorders, chronic pain, neurological diseases, hormonal 
imbalances, and smoking cessation, where continuous and controlled drug delivery is essential. 
However, the skin functions as a highly efficient protective barrier, restricting the permeation of 
most therapeutic agents.